澳大利亚

我们是谁

  • 5 月 23, 2022
    索托拉西布和帕尼单抗与研究者选择治疗克氏鼠肉瘤（KRAS）p.G12C 突变患者（代码 300）
  • 4 月 5, 2022
    Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors
  • 4 月 5, 2022
    A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
  • 4 月 5, 2022
    在晚期实体瘤受试者中评估 MEDI5752 的研究
  • 4 月 5, 2022
    BMS-986253与Nivolumab或Nivolumab加Ipilimumab联合治疗晚期癌症的研究
  • 4 月 5, 2022
    评估THOR-707对晚期或转移性实体瘤成人受试者安全性和治疗活性的研究
  • 4 月 5, 2022
    肿瘤诊断精准免疫肿瘤学和体细胞靶向合理性（TAPISTRY）平台研究
  • 4 月 5, 2022
    一项针对晚期实体瘤患者的BMS-986340单药及与Nivolumab联合用药研究
  • 4 月 5, 2022
    Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
  • 4 月 5, 2022
    A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors